Varenicline

Varenicline is a prescription medication for smoking cessation that partially activates α4β2 nicotinic acetylcholine receptors while reducing nicotine’s rewarding effects.

α4β2 Nicotinic Acetylcholine Receptor: A neuronal acetylcholine receptor subtype strongly involved in nicotine dependence and reward. Varenicline binds this receptor subtype to produce its central therapeutic effects.
Smoking Cessation: The process of stopping tobacco use and maintaining abstinence. Varenicline is used as a medication to support this process.
Nicotine Replacement Therapy: Treatment that supplies nicotine in controlled forms to reduce withdrawal while stopping tobacco use. Unlike replacement therapy, varenicline does not deliver nicotine.
Pfizer: An American pharmaceutical company that developed and markets medicines and vaccines. Pfizer developed varenicline and introduced it under the brand name Chantix.
Partial Agonist: A substance that activates a receptor but produces a smaller maximal response than a full agonist. Varenicline’s partial agonism explains how it can relieve craving while limiting nicotine’s added reward.
Nicotine Withdrawal: A cluster of symptoms that can follow stopping or reducing nicotine use. Varenicline’s receptor activity can reduce withdrawal symptoms during quitting.
Bupropion: An antidepressant also prescribed to help people stop smoking. Bupropion supports cessation through different pharmacology rather than nicotinic receptor partial agonism.
Chantix: The former United States brand name for varenicline. This brand name identifies varenicline in its original U.S. marketing.
Nicotine: An addictive alkaloid in tobacco that stimulates nicotinic acetylcholine receptors. Varenicline competes with nicotine at receptors involved in dependence.
Smoking Cessation Guidelines: Clinical recommendations for helping people stop using tobacco. Guidelines place varenicline among evidence-based medication options for cessation.

Linked from 6 pages